1887

Abstract

The aim of this study was to determine the prevalence and antibiotic resistance rates of extended-spectrum -lactamase (ESBL)-producing strains isolated from inpatients at the Split University Hospital (southern Croatia) during a survey performed between 2005 and 2008. A total of 2152 consecutive isolates of were isolated. The prevalence was 0.5 % in 2005 and increased significantly to 20.9 % by 2008. Strains were most frequently isolated from urine (36.5 %) and bronchial aspirates and wound swabs (11.3 %). ESBL-producing isolates showed very high resistance rates to the majority of non--lactam antibiotics and were susceptible to a -lactam/-lactamase inhibitor and carbapenems. The isolates were genotyped and their ESBLs were molecularly characterized. Strains originating from the intensive care unit and the surgery and neurosurgery wards were clonally related. All isolates produced the TEM-52 type of ESBL. To the best of our knowledge, our work detailed here and summarized in an earlier communication is the first report of such isolates from southern Croatia. Increased monitoring and screening for ESBL production in this species at our hospital is mandatory.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.016964-0
2010-10-01
2024-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/10/1185.html?itemId=/content/journal/jmm/10.1099/jmm.0.016964-0&mimeType=html&fmt=ahah

References

  1. Arlet G., Brami G., Décrè D., Flippo A., Gaillot O., Lagrange P. H., Philippon A. 1995; Molecular characterisation by PCR-restriction fragment length polymorphism of TEM β -lactamases. FEMS Microbiol Lett 134:203–208
    [Google Scholar]
  2. Biendo M., Thomas D., Laurans G., Hamdad-Daoudi F., Canarelli B., Rousseau F., Castelain S., Eb F. 2005; Molecular diversity of Proteus mirabilis isolates producing extended-spectrum β -lactamases in a French university hospital. Clin Microbiol Infect 11:395–401 [CrossRef]
    [Google Scholar]
  3. Bonnet R., De Champs C., Sirot D., Chanal C., Labia R., Sirot J. 1999; Diversity of TEM mutants in Proteus mirabilis . Antimicrob Agents Chemother 43:2671–2677
    [Google Scholar]
  4. Bradford P. A. 2001; Extended spectrum β -lactamases. Clin Microbiol Rev 14:933–951 [CrossRef]
    [Google Scholar]
  5. Canton R., Coque T. M. 2006; The CTX-M β -lactamase pandemic. Curr Opin Microbiol 9:466–475 [CrossRef]
    [Google Scholar]
  6. CDC 2004; One-day (24–28 h) standardized laboratory protocol for molecular subtyping of Escherichia coli O157 : H7, non-typhoidal Salmonella serotypes, and Shigella sonnei by pulsed field gel electrophoresis. Atlanta: Centers for Disease Control and Prevention http://www.cdc.gov/pulsenet/protocols.htm
  7. CLSI 2008a; Performance Standards for Antimicrobial Disk Susceptibility Tests ; Approved Standard. , 10th edn.M02–A10 Wayne, PA: Clinical and Laboratory Standards Institute;
  8. CLSI 2008b; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ; Approved Standard. , 8th edn.M07–A8 Wayne, PA: Clinical and Laboratory Standards Institute;
  9. Coker C., Poore C. A., Li X., Mobely H. L. 2000; Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect 2:1497–1505 [CrossRef]
    [Google Scholar]
  10. Empel J., Baraniak A., Literacka E., Mrówka A., Fiett J., Sadowy E., Hryniewicz W., Gniadkowski M. the Beta-PL Study Group 2008; Molecular survey of β -lactamases conferring resistance to newer β -lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 52:2449–2454 [CrossRef]
    [Google Scholar]
  11. Fiett J., Palucha A., Miaczynska B., Stankiewicz M., Przondo-Mordarska H., Hryniewicz W., Gniadkowski M. 2000; A novel complex mutant β -lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β -lactamase-producing Klebsiellae . Antimicrob Agents Chemother 44:1499–1505 [CrossRef]
    [Google Scholar]
  12. Ho P. L., Chow K. H., Yuen K. Y., Ng W. S., Chau P. Y. 1998; Comparison of a novel, inhibitor-potentiated disc-diffusion test with other methods for the detection of extended-spectrum β -lactamases in Escherichia coli and Klebsiella pneumoniae . J Antimicrob Chemother 42:49–54 [CrossRef]
    [Google Scholar]
  13. Jarlier V., Nicolas M. H., Fournier G., Philippon A. 1988; Extended broad-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae : hospital prevalence and susceptibility patterns. Rev Infect Dis 10:867–878 [CrossRef]
    [Google Scholar]
  14. Jean S. S., Hsueh P. R., Lee W. S., Chang H. T., Chou M. Y., Chen I. S., Wang J. H., Lin C. F., Shyr J. M. other authors 2009; Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 28:215–220 [CrossRef]
    [Google Scholar]
  15. Lau S. H., Kaufmann M. E., Livermore D. M., Woodford N., Willshaw G. A., Cheasty T., Stamper K., Reddy S., Cheesbrough J. other authors 2008; UK epidemic Escherichia coli strains A–E, with CTX-M-15 β -lactamase, all belong to the international O25 : H4-ST131 clone. J Antimicrob Chemother 62:1241–1244 [CrossRef]
    [Google Scholar]
  16. Livermore D. M. 1998; β -Lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 41:25–41
    [Google Scholar]
  17. Nijssen S., Florijn A., Bonten M. J., Schmitz F. J., Verhoef J., Fluit A. C. 2004; Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 24:585–591 [CrossRef]
    [Google Scholar]
  18. Nüesch-Inderbinen M. T., Hächler H., Kayser F. H. 1996; Detection of genes coding for extended-spectrum SHV β -lactamases in clinical isolates by a molecular genetic method, and comparison with E test. Eur J Clin Microbiol Infect Dis 15:398–402 [CrossRef]
    [Google Scholar]
  19. Pitout J. D., Wei Y., Church D. L., Gregson D. B. 2008; Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6′)-Ib-cr . J Antimicrob Chemother 61:999–1002 [CrossRef]
    [Google Scholar]
  20. Poyart C., Mugnier P., Quesne G., Berche P., Trieu-Cuot P. 1998; A novel extended-spectrum TEM-type β -lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae . Antimicrob Agents Chemother 42:108–113
    [Google Scholar]
  21. Sardelic S., Bedenic B., Colinon C., Sijak D., Kalenic S. 2009; First report of TEM-52 lactamase in Proteus mirabilis strains from Croatia. Clin Microbiol Infect 15:1204
    [Google Scholar]
  22. Spanu T., Luzzaro F., Perilli M., Amicosante G., Toniolo A., Fadda G. the Italian ESBL Study Group 2002; Occurrence of extended-spectrum β -lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β -lactams and other antimicrobial drugs. Antimicrob Agents Chemother 46:196–202 [CrossRef]
    [Google Scholar]
  23. Tonkic M., Goic-Barisic I., Punda-Polic V. 2005; Prevalence and antimicrobial resistance of extended-spectrum β -lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol 8:119–124
    [Google Scholar]
  24. Tonkić M., Goić-Barišić I., Novak A., Karanović J., Šiško-Kraljević K., Mohar B., Punda-Polić V. 2008; Prevalence and antibiotic resistance of extended-spectrum β -lactamases (ESBLs)-producing Proteus mirabilis strains at University Hospital Split. In Abstracts Book of the 8th Croatian Congress of Clinical Microbiology with International Participation Zagreb: 25–28 May 2008 pp 43–45 Edited by Kalenić S. Zagreb: Croatian Society of Medical Microbiology and Parasitology;
    [Google Scholar]
  25. Winokur P. L., Canton R., Casellas J. M., Legakis N. 2001; Variation in the prevalence of strains expressing an extended-spectrum β -lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 32:S94–S103 [CrossRef]
    [Google Scholar]
  26. Woodford N., Ward M. E., Kaufmann M. E., Turton J., Fagan E. J., James D., Johnson A. P., Pike R., Warner M. other authors 2004; Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β -lactamases in the UK. J Antimicrob Chemother 54:735–743 [CrossRef]
    [Google Scholar]
  27. Woodford N., Fagan E. J., Ellington M. J. 2005; Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β -lactamases. J Antimicrob Chemother 57:154–155 [CrossRef]
    [Google Scholar]
  28. Zong Z., Partridge S. R., Thomas L., Iredell J. R. 2008; Dominance of bla CTX-M within an Australian extended-spectrum β -lactamase gene pool. Antimicrob Agents Chemother 52:4198–4202 [CrossRef]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.016964-0
Loading
/content/journal/jmm/10.1099/jmm.0.016964-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error